FREE USPS SHIPPING OVER $150Order by 12 PM Pacific Time for same-day shippingSpend $300, get a free Retatrutide 10mg or Wolverine 10mg (BPC-157 5mg + TB-500 5mg) · ends Nov 30

Home / Guides / handling

Tesamorelin storage and stability: what shortens the shelf life, and what protects it

handlingUpdated 2026-08-26Reviewed by Mike Vance, Chief Research OfficerResearch use only
Tesamorelin research vial with its LabFirst lot label
Short answer

For tesamorelin storage and stability, keep the lyophilized powder sealed, dry, dark and cold. Moisture governs the outcome more than freezer temperature does. Its single methionine and an Asn-Ser motif are the residues to watch, and condensation on cold glass is the usual way water gets in.

Key facts
  • Storage conditions in tesamorelin prescribing information describe formulated sterile products and do not transfer to an unformulated research powder.
  • Tesamorelin is the 44-residue GRF backbone with a trans-3-hexenoyl group on Tyr1, around 5136 Da, containing one methionine and no cysteine.
  • The Asn8-Ser9 motif makes deamidation the most likely first-appearing degradation product on RP-HPLC.
  • Moisture, not freezer temperature, is the dominant driver for a dry peptide, and condensation on a cold vial is the usual delivery route.
  • A research lot without its own stability study has an unestablished shelf life, whatever number the packaging carries.

What this guide covers

Think of it like a packet of instant coffee. Sealed and dry, it keeps for a long time. Once damp air gets in it starts to change, and the cold of the cupboard matters far less than keeping it dry.

This guide covers storage for research-grade tesamorelin: what the sequence predicts, which routes break it down, the conditions that suit each physical state, opening a cold vial without letting water in, and what belongs in the lab record.

Search for tesamorelin storage conditions and you will mostly find figures lifted from the prescribing information for an approved product. Those numbers are real, and they are earned: they come from stability studies run on a specific sterile formulation, in a specific container closure, with mannitol as a bulking agent and a defined water-for-injection diluent. They describe that article of manufacture and nothing else.

The comparison still teaches something, because the tesamorelin labeling has changed. The original approved presentation carried refrigerated storage. A later reformulation of the same active moiety carries room-temperature storage in its labeling. Same peptide, different excipient system, different assigned condition. That difference exists because storage conditions are a property of the formulation, not of the amino acid sequence.

A research vial of lyophilized tesamorelin has no formulation study behind it. Usually it has no excipient matrix either, or a minimal one the certificate may or may not name. Copying either labeled condition onto that vial is guesswork wearing a lab coat. What can be reasoned about honestly is the chemistry of the sequence, the physics of a dry cake in a sealed vial, and what changes the moment someone adds water. That is what follows.

At a glanceWhere a lyophilized tesamorelin vial actually loses purity
  • Moisture into the cake, usually from condensation on cold glass
  • Deamidation at Asn8-Ser9 once water is present
  • Oxidation of Met27 from headspace oxygen and light
  • Hydrolysis at Asp3 and Asp25 under moisture and heat
  • Surface adsorption of the hydrophobic N-terminal region

What does the tesamorelin sequence predict about stability?

Tesamorelin is the 44-residue human growth hormone-releasing factor backbone carrying a trans-3-hexenoyl group on the N-terminal tyrosine. Reported molecular formula is C221H366N72O67S with a monoisotopic-adjacent average mass near 5136 Da. The single sulfur in that formula is the whole story of its oxidation behavior: one methionine, at position 27, and no cysteine anywhere. There is no disulfide to scramble and no free thiol to dimerize, which removes an entire failure category that complicates many peptides of this size.

What remains is worth reading residue by residue. Asparagine 8 is followed immediately by serine. Asn-Ser is one of the faster deamidation motifs in the literature on peptide backbones, second in practice only to Asn-Gly, and it sits close enough to the N-terminus that a deamidated species will often separate cleanly on a reversed-phase gradient. Asparagine 35 sits next to glutamine. Aspartate 3 and aspartate 25 are candidates for isomerization and for the slow Asp-Xaa cleavage that shows up as a low-mass fragment on LC-MS long before it shows up as anything visible.

The hexenoyl cap is the part I would not overclaim about. It is a short unsaturated acyl chain, and an alkene is in principle an oxidation target, but I am not aware of published forced-degradation work that quantifies that route for this molecule specifically. Treat it as a plausible pathway to look for rather than an established one. The cap also makes the N-terminus more hydrophobic than the parent peptide, which matters mainly for retention time on RP-HPLC and for a modest amount of surface adsorption at low concentration.

Which degradation routes matter, and what controls each?

Failure modes relevant to lyophilized tesamorelin
RouteDriverSite in this moleculeControl
DeamidationWater activity, temperature, pH above about 6Asn8-Ser9 primarily; Asn35; glutamines more slowlyKeep the solid dry
OxidationHeadspace oxygen, light, trace metalsMet27; possibly the hexenoyl alkeneDark storage, cold, low headspace
Backbone hydrolysis and Asp cleavageMoisture, heat, acidic pHAsp3, Asp25Dry sealed solid
AggregationAir-water interface, agitation, freeze-thawWhole molecule; a 44-mer with hydrophobic patchesAvoid agitation and repeated freeze-thaw
Surface adsorptionGlass and some plastics at low concentrationHydrophobic N-terminal regionDocumented container material

Two of those rows share a driver. Deamidation and hydrolysis both need water, which is why a dry cake sits in a much slower regime than any solution at any temperature. Cold slows every row in the table, but it changes rates rather than mechanisms. Moisture is the mechanism.

What conditions suit each physical state?

Handling conditions, with the reasoning attached
StateTemperatureLightRelative horizonWhy
Sealed powder, reserve stockMinus 20 °C or below, desiccatedDarkLongestWater excluded and every rate suppressed
Sealed powder, in use2 to 8 °C, desiccatedDarkShorterAdequate where the vial is consumed inside a defined window
Powder in transitAmbient, insulatedDarkDaysA dry solid tolerates short excursions; a solution does not

The horizons are relative on purpose. Assigning months to a research lot requires a stability study on that lot, in that closure, under those conditions, of the kind ICH Q1A(R2) describes for registered products. Absent that study the window is unestablished, and a supplier quoting twenty-four months for a powder they have not tested is repeating a convention. The lot's own certificate is the only paper entitled to carry a date, and where it carries none, say so in your record instead of inventing one.

Opening a sealed vial without condensation, step by step

The most common avoidable loss happens in about thirty seconds. A vial comes out of a minus twenty freezer into a room at 22 °C and 55 percent relative humidity. Glass at that temperature is far below the dew point. Break the seal and moist room air meets a cold, hygroscopic cake, and water goes into the solid immediately. Then the vial returns to the freezer with the water inside it, and the next person repeats the sequence.

Nothing about this announces itself. A cake that has taken up a percent or two of moisture looks identical to one that has not. The only symptom is a purity number that drifts downward across a lot's working life, by which point the cause is weeks in the past and unrecorded.

The control is dull, and it goes like this:

  1. Let the sealed vial equilibrate to room temperature before the seal is broken, every time. Twenty to thirty minutes on the bench suits a small vial; put it in a closed box so it warms in the dark.
  2. Break the seal and work briskly once it is open.
  3. Reseal with the vial in a desiccator or against fresh desiccant.
  4. Note the excursion if your protocol tracks openings.
  5. Where a lot will be sampled repeatedly, split the dry powder into several vials once, under low humidity, and never open the reserve again.

Drier is not automatically better in every formulation, incidentally. Residual moisture plays a structural role in some lyophilizates, and the optimum for a sugar-containing cake is not always the lowest achievable water content. That is a formulation finding rather than a storage instruction. For an unformulated research powder, exclude water and stop worrying about the nuance.

What does the storage record have to say?

Storage discipline that is not written down is not reproducible, and for a peptide with a fast deamidation motif the record is what lets you tell a bad lot from bad handling. The minimum entry for each vial names the source lot, the certificate revision it corresponds to, the date received, where it was stored and who checked it.

Add two fields most logs omit: the number of times the parent dry vial has been opened, and whether it was equilibrated before opening. Those are the entries that explain a purity result twelve weeks later.

On the incoming side, read the certificate before the vial goes into storage. For tesamorelin the useful boxes are an RP-HPLC purity figure with the gradient and column stated, a mass confirmation consistent with roughly 5136 Da for the intact molecule, water content, and counterion or acetate content, since a peptide supplied as an acetate salt weighs more than the free peptide and the net peptide content changes how much peptide the vial holds. Our documentation standard sets out which of those we treat as non-negotiable. The same reading applies to any peptide; the tirzepatide handling guide works through the equivalent for a lipidated sequence.

This page stops at the sealed vial.

Red flags in tesamorelin storage and handling

  • A supplier quoting twenty-four months for a powder it has not tested. That is a convention being repeated.
  • A storage condition copied from the approved product's labeling onto a research vial.
  • A freezer vial that gets opened cold, and opened often.
  • A cake that has shrunk or gone glassy, which suggests it went above its glass transition temperature at some point.
  • A certificate with no water content and no counterion or acetate figure.

Any one of these is a reason to look harder at the lot record before trusting a purity result.

What is the regulatory position of tesamorelin?

An approved medicine exists. This material is not it

Tesamorelin is a growth hormone-releasing factor analog. FDA approved tesamorelin acetate as a prescription medicine in 2010 for a specific indication in HIV-associated lipodystrophy, and a later reformulation of the same active moiety is also approved. Those products are sterile, formulated, released under pharmaceutical quality systems, and available only on prescription.

Research-grade lyophilized powder is a different article. It is supplied against a certificate of analysis covering identity and purity, which is a narrower claim about a different kind of material, and it has never been a lawful route to human use at any point in that timeline. Growth hormone-releasing factors and their analogs, tesamorelin included, are also prohibited at all times under the World Anti-Doping Agency prohibited list, which is relevant to laboratories running anti-doping reference work.

Status verified August 26, 2026.

FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.

Bottom line

Tesamorelin has one methionine, no cysteine and a fast Asn8-Ser9 deamidation motif, so water hurts it more than warmth does. Keep the sealed powder dry and dark in the cold, let a cold vial reach room temperature before you open it. The storage numbers on the approved product belong to that formulation. For a research vial, only the lot's own certificate is entitled to carry a date.

Common questions

Should lyophilized tesamorelin be frozen or refrigerated?

Frozen and desiccated is the slower regime for long-term reserve stock, refrigerated is usually adequate for a vial being consumed inside a defined window. The choice matters less than whether the vial is dry and whether it is equilibrated before opening. A frequently opened freezer vial can end up worse than a carefully handled refrigerated one, because every cold opening admits condensation into the cake.

Which degradation product should I expect to see first on HPLC?

Most often a deamidated species, given the Asn8-Ser9 motif, appearing as a shoulder or a resolved peak close to the main band. Methionine sulfoxide from Met27 is the other early candidate and usually shifts earlier on a reversed-phase gradient. Confirm with LC-MS rather than retention time alone: plus one Dalton for deamidation, plus sixteen for a sulfoxide.

Does the room-temperature labeling on the approved product mean the powder is heat-stable?

No. That condition belongs to a specific sterile formulation with its own excipient system and container closure, supported by stability studies on that article. An unformulated research powder has none of that behind it. Read the labeled condition as evidence that the molecule can be stabilized at room temperature by formulation, not as permission to leave your vial on a bench.

Why does the certificate list acetate content?

Because most synthetic peptides are isolated as acetate or trifluoroacetate salts, and the salt weighs more than the free peptide. If a vial is labeled 5 mg of gross material at, say, 88 percent net peptide content, the actual peptide mass is lower than the label suggests. Net peptide content, water content and counterion figures together let you correct the figure.

Is a cake that has shrunk or gone glassy still usable?

It is a signal, not a verdict. Collapse or a glassy appearance suggests the material went above its glass transition temperature at some point, usually with moisture involved, and both correlate with degradation. Record the observation, then decide on analysis rather than appearance. If a purity re-check is not available, treat the vial as suspect and do not let it silently become the reference lot.

Sources

  • FDA prescribing information for tesamorelin acetate for injection. Establishes the approval of tesamorelin as a prescription medicine, its excipient system including mannitol, and the assigned storage conditions for the formulated product, including the difference in condition between the original presentation and the later reformulation.
  • Butreddy et al., International Journal of Biological Macromolecules, 2020. Review of stresses, stabilization mechanisms and analytical methods for lyophilized protein and peptide products; supports the degradation-route table and the primacy of solid-state, moisture-controlled storage.
  • Manning, Chou, Murphy, Payne and Katayama. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 27(4):544-575 2010. Basis for the chemical and physical degradation routes described here — the review covers both, and the interaction between them, for peptide and protein pharmaceuticals.
  • ICH Q1A(R2), Stability Testing of New Drug Substances and Products. Defines what a stability study must contain before a shelf life can be assigned; supports the position that an untested research lot has an unestablished window.
FROM THE BENCH

Lot reports, storage data, and what we learn testing them.

A short note when new certificates post, when a stability result surprises us, and when a guide worth reading goes up. No promotions.

Research correspondence only. Unsubscribe in one click. We never sell or share an address.

Shop the compounds

Tesamorelin storage and stability: what shortens the shelf life, and what protects it research vial, supplied with lot-specific documentationRetatrutideSizes, price per mg and lot certificateTesamorelin storage and stability: what shortens the shelf life, and what protects it research vial, supplied with lot-specific documentationTirzepatideSizes, price per mg and lot certificateTesamorelin storage and stability: what shortens the shelf life, and what protects it research vial, supplied with lot-specific documentationSemaglutideSizes, price per mg and lot certificateTesamorelin storage and stability: what shortens the shelf life, and what protects it research vial, supplied with lot-specific documentationBPC 157Sizes, price per mg and lot certificateTesamorelin storage and stability: what shortens the shelf life, and what protects it research vial, supplied with lot-specific documentationGHK-CuSizes, price per mg and lot certificateTesamorelin storage and stability: what shortens the shelf life, and what protects it research vial, supplied with lot-specific documentationTB-500Sizes, price per mg and lot certificate
Browse all compounds